Stereotaxis announced the publication of initial clinical results for its MAGiC robotic magnetic navigation ablation catheter in the Journal of Interventional Cardiac Electrophysiology. The study demonstrated a 94% acute efficacy rate in treating various arrhythmias across all four heart chambers. This is the first peer-reviewed publication supporting the safety and efficacy of the MAGiC catheter.
This publication is a critical step for Stereotaxis as it launches the MAGiC catheter in Europe. The positive results, particularly the high acute efficacy and low adverse event rate, provide crucial validation for physicians considering adopting this new technology. This peer-reviewed data strengthens Stereotaxis’s position in the robotic cardiac ablation market and builds confidence among potential customers. The findings also contribute significantly to the growing body of evidence supporting robotic navigation in minimally invasive cardiac procedures, potentially influencing clinical practice and treatment guidelines.
The study, a prospective, multi-center, single-arm trial, enrolled 67 patients with diverse arrhythmias. Key findings include a 94% acute efficacy rate, comparable or superior to results from larger registries using other ablation catheters. Average procedure time was 83 minutes, and the adverse event rate was a low 1.5%, attributed to known risks of the procedure and not catheter malfunction. The study authors, experienced in robotic procedures, highlighted the improved stability of the MAGiC catheter, eliminating the need for support sheaths, maintaining stable catheter tip temperatures, and using low irrigation rates, which benefits patients with compromised cardiac and renal function.
This positive publication reinforces the potential of the MAGiC catheter to become a leading technology in robotic cardiac ablation. The data supports broader adoption in Europe and potentially paves the way for future regulatory approvals and market expansion. It also underscores Stereotaxis’s commitment to advancing robotic technologies for minimally invasive endovascular surgery, potentially driving innovation and improved patient outcomes in this field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
